The review arrives at a moment of growing frustration in breast cancer management. Although surgery, chemotherapy, radiotherapy, endocrine therapy, and targeted agents have dramatically improved outcomes for many patients, a substantial proportion still experience recurrence and progression. One reason is that breast cancer is not a single disease. Its molecular subtypes—luminal A, luminal B, HER2-positive, and triple-negative breast cancer (TNBC)—each carry distinct biological behaviors, respond differently to the same drugs, and recur at different rates. Clinicians have long sought biomarkers that can be measured after diagnosis to guide treatment decisions in real time, and metabolites are emerging as unusually informative candidates.

The logic behind metabolomics is rooted in a fundamental feature of cancer biology. Tumor cells rewire their metabolic machinery to sustain energy production, maintain redox balance, and fuel relentless biosynthesis even under the hostile conditions of hypoxia and nutrient scarcity that characterize the tumor microenvironment. Because metabolites sit at the very end of the chain linking genes to proteins to cellular function, they offer a dynamic and sensitive readout of what a tumor is actually doing—often a more faithful snapshot of phenotype than genomic or proteomic data alone. Metabolites also participate directly in signaling, immune evasion, and epigenetic modification, meaning they are not merely passive byproducts but active participants in malignant progression.

To build their evidence map, the researchers conducted a systematic PubMed search covering studies published between 2006 and 2025, screening 445 initial hits down to 53 clinical studies involving human biological samples. Of these, 36 addressed metabolomics for monitoring therapeutic response, 9 focused on prognostic markers, and 8 examined signatures of disease progression. The studies drew on a variety of biological materials—serum most commonly, followed by plasma, tumor tissue, urine, and feces—and employed a range of analytical platforms. Liquid chromatography-mass spectrometry (LC-MS) dominated the field, with nuclear magnetic resonance (NMR) spectroscopy and gas chromatography-mass spectrometry (GC-MS) as important alternatives. Most studies (41) used untargeted approaches that survey the metabolome broadly, while 7 used targeted methods and 5 combined both strategies.

One of the review’s most striking findings is how rapidly cancer treatments themselves reshape the metabolic landscape. Within the first 24 hours of paclitaxel administration, patients show significant changes in plasma concentrations of 2-hydroxybutyrate, 3-hydroxybutyrate, pyruvate, and several amino acids involved in the TCA cycle and glycolysis. Longer courses of chemotherapy perturb sphingolipid metabolism and the biosynthesis of phenylalanine, tyrosine, and tryptophan, while adjuvant regimens alter tyrosine metabolism, lysine degradation, and branched-chain amino acid synthesis. Targeted therapies leave their own fingerprints: anti-HER2 treatment elevates plasma methionine in metastatic patients, and trastuzumab increases pantothenic acid, taurine, and L-histidine in early breast cancer. Even surgery and radiotherapy produce detectable shifts. Post-surgical plasma shows rises in sucrose—possibly reflecting prolonged physiological stress—and dodecanoic acid, an apoptosis-inducing fatty acid suggesting metabolic recovery after tumor removal. Remarkably, radiotherapy shifted several serum metabolites, including leucine, isoleucine, and lactate, toward levels observed in healthy individuals, hinting at partial metabolic normalization.

Beyond documenting these shifts, the review highlights metabolomics’ real clinical promise: predicting who will respond to neoadjuvant chemotherapy (NAC), the treatment given before surgery to shrink tumors. Achieving a pathological complete response (pCR) after NAC strongly predicts better survival, so knowing in advance who will benefit is invaluable. Here, the studies reveal subtype-specific patterns. In HER2-positive breast cancer, two independent studies found that elevated pre-treatment serum spermidine predicted good response to NAC combined with anti-HER2 agents. This polyamine likely works through antitumor immunity—intratumoral spermidine accumulation correlates with activated CD8+ T cells, and high tumor-infiltrating lymphocytes are known to predict better NAC response in this subtype.

In TNBC, the picture is more complex but equally intriguing. Poor responders showed increases in chlorokynurenine, anthranilic acid, and 3-hydroxykynurenine in pre-treatment plasma, along with elevated acetylated polyamines—pointing to altered tryptophan and polyamine metabolism, both deeply intertwined with immune regulation. Another study found that responders had decreased plasma trimethylamine N-oxide (TMAO), a gut microbiota-produced metabolite previously shown to activate endoplasmic reticulum stress kinase PERK, triggering gasdermin E-mediated pyroptosis in tumor cells and enhancing CD8+ T cell-mediated antitumor immunity. Even fecal metabolites have entered the picture: an NMR study of luminal breast cancer found that good NAC responders excreted higher levels of amino acids such as methionine, valine, alanine, and isoleucine—possibly reflecting reduced tumor demand for these building blocks as the cancer shrank. This noninvasive sampling approach also underscores the interplay between gut microbiota and chemotherapy efficacy.

Metabolomics may also forecast the dark side of treatment. The review cataloged studies linking metabolic signatures to chemotherapy-induced peripheral neuropathy, hypersensitivity reactions, cardiometabolic complications, pain, fatigue, and long-term neurologic toxicity. Histidine emerged as a recurring culprit: levels of this essential amino acid predicted the severity of paclitaxel-induced neuropathy and differed between patients who experienced doxorubicin-related hypersensitivity and those who did not. Mechanistically, histidine is converted by histidine decarboxylase into histamine, the classic mediator of allergic responses and an inflammatory neuromodulator. Aromatase inhibitor-related musculoskeletal symptoms—common in postmenopausal patients on long-term endocrine therapy—were associated with upregulated organic acids and downregulated lipid and sphingolipid pathways. Even radiotherapy-induced skin reactions showed a metabolic signature involving 13 markers, including ethanolamine and thymine, with alanine, aspartate, and glutamate metabolism most significantly altered. Such pharmacometabolomics could one day enable early intervention and dose modification before toxicity becomes debilitating.

For disease monitoring, metabolomics offers the tantalizing prospect of catching recurrence before imaging can. Patients with recurrent breast cancer exhibited significantly lower serum levels of formate, histidine, proline, choline, glutamic acid, and other metabolites compared with non-recurrent patients, with branched-chain amino acid metabolism—specifically the degradation of valine, leucine, and isoleucine—showing significant disruption. A multicenter study of preoperative serum in ER-positive early breast cancer identified a metabolite signature that independently predicted recurrence regardless of clinicopathological factors, with recurrent patients showing elevated valine, leucine, isoleucine, choline, phenylalanine, histidine, glycine, tyrosine, and lactate. The involvement of branched-chain amino acids makes biological sense: they fuel the TCA cycle for ATP production, activate mTOR signaling to drive proliferation, and valine specifically promotes cell-cycle progression through translational regulation of cyclin D2. Metabolic signatures also shift across disease stages and metastatic sites. Early-stage disease shows predominant carbohydrate metabolism, stage II features disrupted glycerophospholipid remodeling, and metastatic patients display elevated acetoacetate, ketone bodies, phenylalanine, and glutamate—the latter fueling invasion through glutathione production and the system Xc-antiporter. A 15-metabolite panel predicted brain metastasis with 96.9% accuracy.

Prognostically, the most consistent signal across studies is lactate. Elevated lactate and glycine in tumor tissue, and elevated lactate and pyruvate in serum, correlate with reduced relapse-free survival and overall survival, particularly in ER-positive patients. Lactate is far more than waste: it acidifies the tumor microenvironment to promote invasion, stimulates angiogenesis through hypoxia-related pathways, suppresses cytotoxic T cells and natural killer cells, renders tumors resistant to radiotherapy, and even regulates gene expression through lactylation, a post-translational modification that drives tumor progression. Bile acids tell a contrasting story: glycochenodeoxycholate levels were positively associated with survival and inversely correlated with tumor proliferation scores. In TNBC, elevated plasma diacetylspermine, a spermine catabolite, marked increased metastasis risk and poorer survival.

The authors are candid about the field’s obstacles. Analytical platforms differ in sensitivity and metabolite coverage, sample handling varies widely, chemotherapy regimens are often pooled in ways that obscure drug-specific effects, and definitions of response differ between studies using pCR, residual cancer burden, RECIST criteria, or survival endpoints. Small sample sizes—ranging from 8 to 699 patients—compound the problem, and confounders such as diet, comorbidities, and smoking are often unaddressed. Only a minority of studies performed subtype-specific analyses or integrated metabolomics with other omics layers. The review calls for large, multi-institutional prospective trials with standardized protocols, longitudinal sampling designs, and multi-omics integration.

Still, the trajectory is clear. Metabolomics offers something conventional biomarkers and imaging cannot: the ability to detect early biochemical perturbations that precede visible disease change, from a noninvasive blood sample, repeatedly over time. If the field can achieve the standardization the authors demand, metabolic fingerprints—especially when fused with genomic and transcriptomic data—could transform breast cancer from a disease managed by population averages into one monitored molecule by molecule, patient by patient.

One of the most significant strides involves the identification of a novel blood-based biomarker predictive of cancer risk in individuals carrying Lynch Syndrome (LS), a hereditary condition that markedly increases the likelihood of colorectal and other cancers. The biomarker detects early immune activity signatures, especially pertaining to T cell responses, among asymptomatic LS carriers. This revelation permits clinicians to stratify patients by their individualized cancer risk, providing a tailored framework for vigilant surveillance and intervention before malignancy develops. Spearheaded by Dr. Eduardo Vilar-Sanchez, Chair ad interim of Clinical Cancer Prevention, the research sheds light on previously uncharted immune dynamics in LS. Dr. Vilar-Sanchez emphasizes the potential of this non-invasive blood assay to revolutionize how medical professionals monitor and manage LS patients, enabling preventative strategies informed by personal immune landscape rather than solely genetic predisposition.

In parallel, a transformative breakthrough targets the formidable challenge of pancreatic cancer’s resistance to immunotherapy. Pancreatic tumors notoriously evade immune-mediated destruction, contributing to dismal survival rates. The research unveiled DPY30, an epigenetic regulator that acts as a replicative stress modulator within cancer cells. This protein’s unique role includes suppressing DNA replication stress pathways that would normally sensitize tumors to immune attack. By inhibiting DPY30, pancreatic tumors may become more vulnerable to immunotherapy regimens. Led by a consortium of scientists including Francesca Citron, Pharm.D., Ph.D., and Andrea Viale, M.D., the study highlights DPY30 as a dual-purpose candidate: a predictive biomarker for patient stratification and a therapeutic target. This dual role is anticipated to unlock novel combination treatment avenues to overcome immune resistance and enrich efficacy for one of the most treatment-refractory cancers.

Addressing resistance phenomena extends beyond pancreatic cancer. Lung cancer’s notable resilience to radiation therapy has stymied curative efforts for decades. Investigators led by Dr. Boyi Gan identified a mitochondrial enzyme, dihydroorotate dehydrogenase (DHODH), as a critical molecular shield that cancer cells deploy to circumvent ferroptosis, a type of iron-dependent cell death induced by radiation. By averting ferroptotic death, tumors maintain viability despite aggressive radiotherapeutic assaults. Importantly, the study revealed that pharmacological inhibition of DHODH with leflunomide—an FDA-approved arthritis drug—restores radiation sensitivity in preclinical lung cancer models. This repurposing strategy offers a rapid translational opportunity, bypassing extensive drug development timelines. Dr. Gan underscores the clinical impact: deciphering the biochemical underpinnings of radioresistance enables tactical interventions to amplify radiotherapy efficacy, a crucial advance in treating lung malignancies where therapeutic options remain limited.

Concurrently, advances in radiation oncology techniques are reshaping treatment protocols for rare and challenging tumor types. Intrahepatic cholangiocarcinoma, a “supermassive” bile duct tumor subset characterized by large hepatic masses, has historically lacked viable radiation options due to significant safety concerns. Yet, a retrospective study led by Drs. Ethan Ludmir and Eugene Koay demonstrated that highly precise, high-dose radiation delivery significantly improves survival outcomes for these patients. Utilizing enhanced imaging and sophisticated dose calculation technologies, clinicians now administer ablative dose radiation safely, overcoming past limitations. Patients receiving this treatment exhibited a median survival more than twice that of cohorts managed solely with chemotherapy. This compelling data advocates for revisiting radiation candidacy criteria for large biliary tumors, leveraging technological progress to convert previously intractable cases into manageable conditions with extended life expectancy.

Collectively, these research initiatives exemplify the synergistic integration of molecular oncology, immunology, epigenetics, and clinical innovation. The LS biomarker stands as a testament to the power of immune profiling to anticipate cancer development, shifting paradigms in hereditary cancer management. Concurrently, dissecting the epigenetic circuitry of pancreatic tumors yields actionable targets poised to enhance immunotherapy, an urgently needed breakthrough in a historically refractory disease. Similarly, elucidation of ferroptosis evasion in lung tumors reveals mechanistic vulnerabilities exploitable via drug repurposing, promising to augment curative radiotherapy regimens. Furthermore, leveraging advanced radiation technologies for large biliary tumors embodies a refined balance of precision and potency, enabling safer administration of higher radiation doses and improved survival.

These discoveries underscore a recurring theme: cancer treatment must transcend one-dimensional approaches. Instead, integrated strategies combining genomic insights, immune modulation, and optimized delivery of cytotoxic therapies offer the best prospects for altering the natural history of aggressive malignancies. The commitment at MD Anderson Cancer Center to bench-to-bedside translation ensures that laboratory findings swiftly inform patient care, expediting the application of novel interventions for enhanced clinical outcomes.

Future directions will likely involve expansive clinical trials evaluating the LS biomarker’s predictive accuracy and utility in guiding surveillance protocols, alongside validation studies assessing DPY30 inhibitors’ combinatorial efficacy with immunotherapies. Similarly, clinical exploration of DHODH inhibitors in conjunction with radiation therapy for lung cancer patients is anticipated, potentially reshaping standard-of-care practices. On the technological front, continuous refinement of radiation delivery platforms promises broader applicability of high-dose protocols for challenging tumor anatomies, facilitating personalized radiation oncology.

In summary, the latest discoveries announced by MD Anderson affirm a future in which cancer risk prediction, resistance mechanism elucidation, and precision treatments converge to overcome monumental therapeutic barriers. As research findings transition into clinical innovation, patients stand to benefit from earlier detection, more effective immunomodulation, and fundamentally improved disease control. The nexus of immunological insight, epigenetic targeting, and radiation science propels oncology toward unprecedented horizons—ushering in a new era of tailored, efficacious, and durable cancer therapies.

Subject of Research: Cancer biomarkers, immunotherapy sensitization, radiation resistance mechanisms, precision radiation therapy

Article Title: Breakthroughs in Cancer Detection and Therapy: Novel Biomarkers, Epigenetic Targets, and Radiation Resistance Strategies Unveiled at MD Anderson

News Publication Date: April 9, 2026

Web References:

• https://www.mdanderson.org/newsroom/research-newsroom/researchers-identify-blood-based-biomarker-for-cancer-risk-in-people-with-Lynch-Syndrome.h00-159854556.html
• https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-25-3849/782666/DPY30-is-an-epigenetic-decoupler-linking
• https://aacrjournals.org/cancerres/article/doi/10.1158/0008-5472.CAN-25-3728/782685/DHODH-Mediated-Suppression-of-Ferroptosis-Supports
• https://aacrjournals.org/clincancerres/article/doi/10.1158/1078-0432.CCR-25-3368/775657/Clinicogenomic-and-Histopathologic-Analyses-of?searchresult=1

References:

• Vilar-Sanchez, E., et al. “Blood-based biomarker for cancer risk estimation in Lynch Syndrome.” Nature Communications, 2026.
• Citron, F., Viale, A., Schlacher, K., Draetta, G. “DPY30 modulates epigenetic replication stress in pancreatic cancer.” Cancer Research, 2026.
• Gan, B., et al. “DHODH mediates ferroptosis resistance in lung cancer radiotherapy.” Cancer Research, 2026.
• Ludmir, E., Koay, E. “High-dose radiation therapy for large intrahepatic cholangiocarcinoma.” Clinical Cancer Research, 2026.

Keywords: Lynch Syndrome, cancer biomarker, T cell response, pancreatic cancer, DPY30, epigenetics, immunotherapy sensitization, lung cancer, radiation resistance, DHODH, ferroptosis, leflunomide, bile duct tumors, intrahepatic cholangiocarcinoma, high-dose radiation therapy, precision oncology

Liquid biopsies represent a transformative advancement in the early detection and ongoing monitoring of various malignancies. Instead of relying solely on traditional tissue biopsies, which can be invasive and uncomfortable for patients, liquid biopsies utilize blood samples to identify biomarkers associated with tumor cells, circulating tumor DNA, or other relevant substances. This innovative technique allows clinicians to glean critical information about a patient’s cancer status, enabling them to make informed decisions about treatment regimens and potential alterations in therapeutic strategies.

Cemiplimab, the immunotherapy agent investigated in this study, has gained traction as an effective treatment option for patients diagnosed with cutaneous squamous cell carcinoma. It operates by targeting the programmed cell death protein 1 (PD-1) pathway, a crucial mechanism that tumors exploit to evade immune detection. By blocking this pathway, cemiplimab enhances the body’s immune response against tumor cells. The current research aims to complement this therapeutic strategy by identifying reliable biomarkers that can predict patient responses to cemiplimab treatment, thereby personalizing therapy for better outcomes.

In a clinical landscape where cancer therapies must increasingly be tailored to individual patients, the identification of liquid biopsy biomarkers serves as a pivotal component of precision oncology. The researchers conducted extensive analyses to evaluate how different biomarkers correlate with patient responses to cemiplimab. Specifically, they focused on liquid samples obtained from patients receiving treatment and evaluated their biochemical profiles using advanced analytical techniques.

The findings of this study highlight the potential of several liquid biopsy biomarkers as predictive tools in estimating the prognosis of patients undergoing treatment for cutaneous squamous cell carcinoma. By stratifying patients based on these biomarkers, oncologists can optimize treatment plans, escalating or de-escalating therapy based on the specific markers present. This dynamic approach not only maximizes therapeutic benefits but also minimizes exposure to unnecessary side effects, reflecting a patient-centered focus in oncological care.

As the study progresses, the implications for future clinical practice are profound. The ability to utilize liquid biopsies for real-time monitoring of treatment responses introduces a revolutionary element in managing cutaneous squamous cell carcinoma. This informs a more fluid and responsive treatment strategy, shifting away from rigid protocols and towards a model that accommodates the dynamic nature of tumor biology. Patients can transcend the uncertainties associated with traditional biopsy methods and gain insights into their disease’s trajectory.

In addition to prognostic capabilities, identifying liquid biopsy biomarkers can deepen the understanding of underlying mechanisms of resistance to cemiplimab. Resistance remains a critical challenge in cancer therapies, particularly in immunotherapy where not all patients exhibit favorable responses. By profiling patients’ liquid biopsies before and during treatment, researchers can glean insights into the biological factors contributing to resistance, paving the way for future research aimed at overcoming these barriers.

Simultaneously, this research underscores the importance of multidisciplinary collaboration in oncology. The roles of pathologists, molecular biologists, bioinformaticians, and oncologists converge to innovate and create novel approaches to cancer treatment leading to improved patient health outcomes. Such collaboration underscores the necessity of integrating diverse expertise in advancing the field of oncology.

As with any scientific endeavor, this study heralds potential limitations that warrant consideration. For instance, the predictive value of biomarkers can vary significantly across patient populations, and thus, broader studies are needed to validate the findings in heterogeneous cohorts. Furthermore, the optimal integration of liquid biopsies into clinical workflows also requires robust standardization and calibration of techniques, ensuring that their utilization in real-world settings is both feasible and beneficial.

Moreover, the ethical implications of using liquid biopsies must also be addressed. As the paradigm shifts to more patient-centered approaches, considerations related to informed consent and data privacy will be paramount. Ensuring that patients understand the processes involved in liquid biopsies, from sample collection to the interpretation of results, as well as its implications for their treatment journey, is essential in fostering trust and transparency in oncological care.

Combining cutting-edge science with real-world applicability, this study by Vanni, Croce, and Pastorino serves as a testament to the evolving landscape of cancer diagnostics and treatment. Liquid biopsy technology is on the verge of transforming how patients with cutaneous squamous cell carcinoma—and potentially other cancers—are managed. The findings set the stage for future research efforts aimed at refining biomarkers and improving therapeutic outcomes.

In summary, the advent of liquid biopsy as a means to enhance prognostic capabilities in immunotherapy signifies a transformative leap in cancer care. By unlocking insights into treatment responses and resistance mechanisms through the study’s findings, the research not only contributes to existing tumor genomics but also promises to improve the quality and effectiveness of personalized cancer therapies.

As further studies build upon these foundational findings, the potential for liquid biopsies to revolutionize cancer diagnostics and treatment paradigms appears more promising than ever. With continued innovation, dedication, and collaboration within the scientific community, the future of oncological care is bright.

Subject of Research: Prognostic Liquid Biopsy Biomarkers in Cutaneous Squamous Cell Carcinoma

Article Title: Identification of prognostic liquid biopsy biomarkers in patients with cutaneous squamous cell carcinoma treated with cemiplimab

Article References:

Vanni, I., Croce, M., Pastorino, L. et al. Identification of prognostic liquid biopsy biomarkers in patients with cutaneous squamous cell carcinoma treated with cemiplimab.
J Transl Med 23, 965 (2025). https://doi.org/10.1186/s12967-025-06957-7

Image Credits: AI Generated

DOI: 10.1186/s12967-025-06957-7

Keywords: Liquid biopsy, cutaneous squamous cell carcinoma, cemiplimab, prognostic biomarkers, immunotherapy, precision oncology.